Core Viewpoint - Guoxin Health (000503) anticipates a net profit loss of 409 million yuan for 2025, primarily due to fair value changes in investment assets, while focusing on core business development in data elements and AI healthcare [1][2]. Financial Performance - For 2025, Guoxin Health expects total revenue of 351 million yuan, remaining stable compared to the previous year; the net profit attributable to shareholders is projected to be -409 million yuan, mainly due to a loss of approximately 260 million yuan from the fair value changes of trading financial assets (Shenzhou Medical Technology) [2]. - The net profit after excluding non-recurring gains and losses is expected to be -148 million yuan, indicating stable performance in core business [2]. Company Status - On February 6, 2026, the company held its 12th board meeting to review a proposal regarding the management of temporarily idle raised funds, with further announcements expected regarding the implementation of this proposal [3]. Industry Policy and Environment - The medical information industry faced overall pressure in 2025, with over half of the companies in the sector forecasting negative net profits excluding non-recurring items. Guoxin Health emphasized its commitment to advancing health big data applications in medical insurance management and quality, aligning with the "Healthy China" and "Three Medical Collaborations" strategies [4]. Stock Performance - As of February 9, 2026, Guoxin Health's stock price is 9.46 yuan per share, with a total market capitalization of 9.264 billion yuan. The stock has increased by 6.53% year-to-date but has decreased by 18.52% over the past 20 days. The net outflow of main funds on that day was 291,700 yuan [5].

Core Viewpoint - The company, Guo Xin Health Assurance Service Group Co., Ltd., has approved the use of idle raised funds for cash management, allowing a maximum of RMB 550 million to be utilized within a specified timeframe to enhance fund efficiency and returns for shareholders [2][6][14]. Group 1: Meeting Details - The 9th meeting of the 12th Board of Directors was held on February 6, 2026, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1][3]. - The meeting adopted a resolution to use idle raised funds for cash management through a named voting process, with unanimous support [2][3]. Group 2: Fund Management Proposal - The company is authorized to use up to RMB 550 million of idle raised funds for cash management, effective for 12 months from the previous authorization expiration, until January 28, 2027 [2][9][14]. - The funds can be used in a rolling manner within the specified limits and timeframe [9][14]. Group 3: Fundraising Background - The company received approval from the China Securities Regulatory Commission on August 23, 2023, to issue shares to specific investors, raising a total of approximately RMB 794.48 million, with a net amount of RMB 782.49 million after deducting issuance costs [7][8]. Group 4: Cash Management Objectives - The purpose of cash management is to utilize temporarily idle funds without affecting the normal investment plans, ensuring fund safety while increasing efficiency and returns for the company and its shareholders [8][13]. Group 5: Investment Guidelines - The company plans to invest in low-risk, high-liquidity financial products, including structured deposits, agreement deposits, and large-denomination certificates of deposit [10]. - The Board has authorized the general manager to make investment decisions within the approved limits and duration [10][14]. Group 6: Approval Process - The proposal was reviewed and approved by the company's audit committee, confirming compliance with necessary procedures and regulations [4][15]. - The sponsor has verified that the cash management plan does not affect the normal investment plans and has recommended enhanced management of raised funds [16][17].

Group 1 - The company Guoxin Health held its 12th ninth board meeting on February 6, 2026, to discuss the proposal for using temporarily idle raised funds for cash management [1] - The central bank, which has been increasing its gold reserves for two consecutive years, announced plans to purchase an additional 150 tons of gold, aiming to stockpile a total of 700 tons [1]

中国银河证券股份有限公司 关于国新健康保障服务集团股份有限公司 使用暂时闲置的募集资金进行现金管理的核查意见 中国银河证券股份有限公司（以下简称"保荐人"）作为国新健康保障服务 集团股份有限公司（以下简称"国新健康"或"公司"）2022 年向特定对象发行 股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司 募集资金监管规则》等有关法规和规范性文件的要求，对国新健康使用暂时闲置 的募集资金进行现金管理的事项进行了核查，具体核查情况如下： 一、募集资金基本情况 中国证券监督管理委员会于 2023 年 8 月 23 日出具了《关于同意国新健康保 障服务集团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕 1899 号），同意公司向特定对象发行股票的注册申请。公司本次向特定对象发行 股票 80,413,268 股，发行价格为 9.88 元/股。根据大信会计师事务所（特殊普通 合伙）出具的《国新健康保障服务集团股份有限公司向特定对象发行股票募集资 金验资报告》（23-00006 号），截至 2023 年 11 ...

证券简称：国新健康 证券代码：000503 编号：2026-05 国新健康保障服务集团股份有限公司 关于使用暂时闲置的募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"或"国新健康"） 于2025年6月5日召开第十二届董事会第二次会议和第十二届监事会第二次会议， 审议通过了《关于增加使用暂时闲置募集资金进行现金管理的额度的议案》，同 意公司（含国新健康保障服务有限公司、国新智康（北京）科技发展有限公司、 国新益康数据（北京）有限公司三家子公司）使用闲置募集资金进行现金管理的 总额度由4.5亿元（含本数）增加至5.5亿元（含本数），使用期限自董事会审议 通过之日起至2026年1月28日止，并由董事会授权公司总经理在上述额度及决议 有效期内行使投资决策权，在前述额度及期限范围内，资金可以循环滚动使用。 为提高公司募集资金使用效率，公司于2026年2月6日召开第十二届董事会第 九次会议，审议通过了《关于使用暂时闲置的募集资金进行现金管理的议案》， 同意公司（含国新健康保障服务有限公司、国新智 ...

证券简称：国新健康 证券代码：000503 编号：2026-04 国新健康保障服务集团股份有限公司 表决结果：9票赞成，0票反对，0票弃权。 本议案已经公司审计委员会审议通过。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网址：www.cninfo.com.cn）披露的《关于使用暂时闲置的募集资金进 行现金管理的公告》（公告编号：2026-05）。 特此公告。 第十二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届董事 会第九次会议于2026年2月4日发出会议通知，会议由董事长李永华先生召集并 主持，于2026年2月6日以现场结合通讯方式召开。本次会议应出席董事9人，实 际出席董事9人，公司高级管理人员列席会议。会议的召开符合有关法律、行政 法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了《关于使用暂时闲置的募集资 金进行现金管理的议案》。同意公司（含本次募投项目实施主体国新健康保障 服务有限公司、国新智康（北京）科技 ...

Group 1 - The company expects to achieve an annual revenue of 351 million yuan for 2025, remaining stable compared to the previous year [1] - The net profit attributable to shareholders is projected to be -409 million yuan, with a net profit of -148 million yuan after excluding non-recurring gains and losses, also stable year-on-year [1] - The decline in performance is primarily due to the underperformance of the company's investment in Shenzhou Medical Technology Co., leading to an expected loss of approximately 260 million yuan from fair value changes of financial assets [1] Group 2 - The company aims to align with the "Healthy China" initiative and the "Three Medical Coordination" reform, focusing on the digitalization and informatization of the healthcare industry [2] - The core strategy revolves around the aggregation, circulation, and application of health big data, targeting areas such as comprehensive management of medical insurance funds and healthcare service innovation [2] - The company is actively exploring investment collaborations to support the "Healthy China" strategy with technical support and professional services [2]

2026年1月30日晚间，国新健康（000503.SZ）发布2025年业绩预告，预计实现营业收入3.51亿元，与去 年同期基本持平；归属于上市公司股东的净利润为-4.09亿元；扣除非经常性损益后的净利润为-1.48亿 元，与去年同期大致持平。在行业整体面临挑战的背景下，国新健康保持住了经营基本面的相对稳定。 行业调整：多重因素导致多家企业集体"深蹲" 从已发布业绩预告的同行企业看，医疗信息化行业2025年正经历一场普遍性的业绩下滑。卫宁健康扣非 净利润由上年盈利转为亏损3.04至3.74亿元；万达信息营业收入与上年基本持平，扣非净利润-5.9 至-6.85亿元；创业慧康扣非净利润-3.15至-4.15亿元，较上年增亏64%-116%；东软集团扣非净利润-3.6 至-4.3亿元，亏损额达到上年10倍以上；嘉和美康扣非净利润-2.46至-2.86亿元，较上年增亏约9.4%。 这一系列数据背后，是医疗信息化行业面临的压力枷锁。行业周期性调整是首要因素。2025年初，国家 卫健委发布《智慧医疗分级评价方法及标准（2025版）》，将评价体系从单一的电子病历系统拓展 为"智慧医疗、智慧服务、智慧管理"三位一体，评级门槛显 ...

Group 1 - The company, Guo Xin Health, is forecasting a loss for the fiscal year 2025, with an expected operating revenue of approximately RMB 351 million, which is roughly in line with the previous year [1][3] - The net profit attributable to shareholders is projected to be around RMB -4.09 billion, primarily due to an expected impairment loss of RMB 260 million on trading financial assets [3][11] - The decline in the value of trading financial assets is linked to the underperformance of Shenzhou Medical Technology Co., Ltd., in which the company holds a 7.66% stake [3][8] Group 2 - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors concerning the forecast [2] - The fair value of the trading financial assets held by the company was approximately RMB 407.81 million at the end of 2024, and it is expected to decrease by RMB 260 million by the end of 2025 [10][11] - The company emphasizes that the financial data presented is preliminary and has not been audited, urging investors to exercise caution [9][11]

格隆汇1月30日丨国新健康(000503.SZ)发布2025年度业绩预告，报告期内，公司实现营业收入约人民币 3.51亿元，基本与上年同期持平；扣除非经常性损益后的净利润为人民币-1.48亿元，基本与上年同期持 平；归属上市公司股东净利润约人民币-4.09亿元。 增亏主要原因为公司的交易性金融资产预计发生减值，该金融资产为公司持有的神州博睿（深圳）投资 企业（有限合伙）99.01%合伙份额。因神州博睿（深圳）投资企业（有限合伙）持有7.66%股份的神州 医疗科技股份有限公司，2025年经营业绩出现下滑，主营业务收入低于预期，预计导致公司交易性金融 资产产生约2.6亿元公允价值变动损失。 ...